<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048892</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0911</org_study_id>
    <secondary_id>COG-ADVL0911</secondary_id>
    <secondary_id>CDR0000663520</secondary_id>
    <nct_id>NCT01048892</nct_id>
  </id_info>
  <brief_title>Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without&#xD;
      damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill&#xD;
      even more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley&#xD;
      virus-001 in treating young patients with relapsed or refractory neuroblastoma,&#xD;
      rhabdomyosarcoma, or rare tumors with neuroendocrine features.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the maximum-tolerated dose and/or recommended phase II dose of Seneca Valley&#xD;
           virus-001 (NTX-010) when administered as a single infusion to pediatric patients with&#xD;
           relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with&#xD;
           neuroendocrine features (Wilms tumor, retinoblastoma, adrenocortical carcinoma, or&#xD;
           carcinoid tumors). (Part A [completed])&#xD;
&#xD;
        -  To confirm that there is viral replication in these patients following NTX-010&#xD;
           administration. (Part A [completed])&#xD;
&#xD;
        -  To define and describe the toxicities of NTX-010 when administered on this schedule.&#xD;
           (Part A [completed])&#xD;
&#xD;
        -  To determine whether the number of regulatory T cells (as measured by flow cytometry)&#xD;
           can effectively be reduced following administration of NTX-010 plus low-dose metronomic&#xD;
           and intravenous cyclophosphamide. (Part B)&#xD;
&#xD;
        -  To characterize the pharmacokinetics (time course of viral clearance) following NTX-010&#xD;
           administration in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To preliminarily define the antitumor activity of NTX-010 within the confines of a phase&#xD;
           I study. (Part A [completed])&#xD;
&#xD;
        -  To evaluate the development of neutralizing antibodies to NTX-010 following IV&#xD;
           administration of NTX-010. (Part A [completed])&#xD;
&#xD;
        -  To evaluate development of neutralizing antibodies to NTX-010 following the combination&#xD;
           of NTX-010 and cyclophosphamide. (Part B)&#xD;
&#xD;
        -  To investigate the presence and permissivity of occult circulating tumor cells prior to&#xD;
           and after the initial intravenous administration of NTX-010.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Part A (completed): Patients receive Seneca Valley virus-001 (NTX-010) IV over 1 hour on day&#xD;
      1.&#xD;
&#xD;
      Part B: Patients receive cyclophosphamide IV orally (PO) on days 1-14 and NTX-010 IV over 1&#xD;
      hour on day 8. In the absence of disease progression or unacceptable toxicity, patients then&#xD;
      receive cyclophosphamide orally (PO) on days 22-35, plus cyclophosphamide IV over 1 hour and&#xD;
      NTX-010 IV over 1 hour on day 29.&#xD;
&#xD;
      Tumor tissue samples are collected at baseline for biomarker studies. Blood and stool samples&#xD;
      are collected periodically for neutralizing antibody and viral clearance studies. Additional&#xD;
      blood samples may also be collected for the presence and permissivity of occult tumor cells.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>12 months post-documented viral clearance</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose of Seneca Valley virus-001 (NTX-010)</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Up to 12 months post documented viral clearance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral titers in blood and stool</measure>
    <time_frame>Up to 56 days post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antibodies to NTX-010</measure>
    <time_frame>Up to 4 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Kidney Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (NTX-010)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seneca Valley virus-001</intervention_name>
    <arm_group_label>Treatment (NTX-010)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Treatment (NTX-010)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Treatment (NTX-010)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Treatment (NTX-010)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Wilms tumor&#xD;
&#xD;
               -  Retinoblastoma&#xD;
&#xD;
               -  Adrenocortical carcinoma&#xD;
&#xD;
               -  Carcinoid tumor&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life&#xD;
&#xD;
          -  No known pulmonary tumors or metastases &gt; 5 cm, as evaluated by chest CT scan&#xD;
&#xD;
          -  No clinically significant pulmonary and/or pericardial effusions (≥ grade 3), as&#xD;
             evaluated by ECHO&#xD;
&#xD;
          -  No primary CNS tumors or known metastatic CNS disease involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (for patients &gt; 16 years of age)&#xD;
&#xD;
          -  Lansky PS 50-100% (for patients ≤ 16 years of age)&#xD;
&#xD;
          -  Peripheral ANC ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (transfusion independent, defined as no platelet&#xD;
             transfusions within a 7-day period before study enrollment)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Creatine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on&#xD;
             age/gender as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (for patients 3 to 5 years of age)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (for patients 6 to 9 years of age)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (for patients 10 to 12 years of age)&#xD;
&#xD;
               -  ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)&#xD;
&#xD;
               -  ≤ 1.7 mg/dL (for male patients ≥ 16 years of age)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT ≤ 110 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Oxygen saturation &gt; 92% on room air&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to comply with the safety monitoring requirements of the study, in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Completely toilet trained&#xD;
&#xD;
          -  No chronic diarrhea or urinary incontinence during the day or night, , and no&#xD;
             in-dwellling urinary catheters&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known pregnant member of the household&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy&#xD;
&#xD;
          -  At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy,&#xD;
             or radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue (without TBI)&#xD;
&#xD;
               -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy or treatment&#xD;
             with therapeutic doses of MIBG&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  More than 7 days since prior growth factor(s) that support platelet or white blood&#xD;
             cell number or function&#xD;
&#xD;
          -  At least 7 days since prior biologic agents&#xD;
&#xD;
          -  At least 3 half-lives since prior monoclonal antibodies&#xD;
&#xD;
          -  More than 7 days since prior viral immunizations, including influenza&#xD;
&#xD;
          -  At least 42 days since the completion of any type of immunotherapy, e.g., tumor&#xD;
             vaccines&#xD;
&#xD;
          -  No other viral immunizations after enrolling on study until 28 days after their last&#xD;
             planned Seneca Valley virus-001 infusion or until documented viral clearance,&#xD;
             whichever is longest&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided the patient has been on a stable or&#xD;
             decreasing dose for the past 7 days&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents (e.g., chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy)&#xD;
&#xD;
          -  Prior treatment with Seneca Valley virus-001 is not allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Burke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley's Children Cancer Center at Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>recurrent adrenocortical carcinoma</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

